Why is Bliss GVS Pharma falling/rising?

As of 23-Jul, Bliss GVS Pharma Ltd's stock is currently priced at 156.85, reflecting a decline of 1.95 points or 1.23%. The stock has been underperforming, having fallen for the last three days with a total decline of 2.82% during this period. In terms of returns, the stock has shown a mixed performance: it has increased by 5.98% over the past month and 39.42% over the past year, but it has decreased by 4.74% year-to-date. Additionally, the stock is currently trading at a premium compared to its peers, and despite a fair valuation indicated by a Price to Book Value of 1.6 and a low Debt to Equity ratio, its profits have decreased by 19.5%, which may be contributing to the recent price decline.
In the broader market context, the stock's short-term performance has been weaker than the benchmark, as it has underperformed the Sensex by 0.66% over the past week while the Sensex has gained 0.11%. The stock's liquidity appears adequate for trading, but there has been a decline in investor participation, with delivery volume falling by 0.3% against the five-day average. This combination of factors, including recent profit declines and lower investor engagement, suggests that while the stock has shown strong long-term performance, its current downward trend may be influenced by immediate market conditions and investor sentiment.